Building strong teams and creating a support system is important in implementing innovation in primary care, according to Alicia Berkemeyer, vice president of Enterprise Primary Care and Pharmacy Programs at Arkansas Blue Cross and Blue Shield.
Building strong teams and creating a support system is important in implementing innovation in primary care, according to Alicia Berkemeyer, vice president of Enterprise Primary Care and Pharmacy Programs at Arkansas Blue Cross and Blue Shield.
Transcript (slightly modified)
What are the challenges of rolling out innovations in primary care?
I think from a practice standpoint, they would tell you just the time has been a challenge and then also some of it is financial because it is very important for them to be able to receive payment in a different fashion these pay management fees for them to have the resources and the support to really build their teams. It’s important to have those teams built in those collaboratives to really have the strong team to make sure everyone is working to the top of their license and doing the appropriate level of outreach and care for the patients. So, I think it’s been very important for them to have that support.
It’s a challenge and it is hard work. It’s not like they can just say “I want to be a patient-centered medical home tomorrow"; it takes time. In reality—in our patient-centered medical home pilot that we did early on, and then also in the conference of primary care for the state of Arkansas—the first couple of years of a medical home, you are going to see your costs increase because you have more compliant patients, you’re having more follow-up care, you’re doing more of your wellness visits. It’s usually around year 3 or 4 that you start seeing the cost savings.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More